A previous study had mentioned that the compact association between the alterations of four main driver genes (KRAS, CDKN2A, SMAD4 and TP53) and the outcome of pancreatic adenocarcinoma patients [4]. This evidence concerns the gene KRAS and pancreatic adenocarcinoma.